<div id="readability-page-1"><ul><li>3 Biotech Stocks That Could Benefit from the Patent Cliff</li></ul><p>CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Brookline Capital Markets dropped their FY2028 earnings per share estimates for CRISPR Therapeutics in a research note issued on Tuesday, May 5th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of $6.91 per share for the year, down from their prior forecast of $7.44. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($4.93) per share.</p><div><p><span></span><span>Get <strong>CRISPR Therapeutics</strong> alerts:</span></p></div><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($1.28) EPS for the quarter, missing analysts' consensus estimates of ($1.22) by ($0.06). The company had revenue of $1.46 million for the quarter, compared to analyst estimates of $6.06 million. CRISPR Therapeutics had a negative return on equity of 25.53% and a negative net margin of 13,856.54%.The company's revenue for the quarter was up 68.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.58) EPS. </p><ul><li>CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows</li></ul><p>A number of other brokerages have also recently commented on CRSP. Piper Sandler  restated an &#34;overweight&#34; rating and set a $110.00 price objective (up from $105.00) on shares of CRISPR Therapeutics in a research note on Tuesday, March 17th. Bank of America dropped their target price on CRISPR Therapeutics from $90.00 to $89.00 and set a &#34;buy&#34; rating on the stock in a research report on Thursday, January 22nd. Citizens Jmp dropped their target price on CRISPR Therapeutics from $86.00 to $80.00 and set a &#34;market outperform&#34; rating on the stock in a research report on Friday, January 30th. TD Cowen lifted their target price on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a &#34;hold&#34; rating in a research report on Friday, February 13th. Finally, Morgan Stanley  reaffirmed an &#34;underweight&#34; rating and set a $33.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. One investment analyst  has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned  a Hold rating and two have assigned  a Sell rating to the company's stock. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $64.53.</p><p><b>Read Our Latest Research Report on CRSP</b></p><h2>CRISPR Therapeutics Price Performance</h2><ul><li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li></ul><p>Shares of CRSP opened at $52.38 on Wednesday. The stock's 50-day moving average is $52.41 and its two-hundred day moving average is $54.60. The stock has a market cap of $5.05 billion, a PE ratio of -8.42 and a beta of 1.74. CRISPR Therapeutics has a 12 month low of $33.03 and a 12 month high of $78.48. </p><h2>Insider Transactions at CRISPR Therapeutics</h2><p>In related news, General Counsel James R. Kasinger sold 3,182 shares of the business's stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $46.78, for a total value of $148,853.96. Following the completion of the sale, the general counsel directly owned 94,308 shares of the company's stock, valued at $4,411,728.24. The trade was a 3.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Also, CEO Samarth Kulkarni sold 10,020 shares of the business's stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $468,735.60. Following the completion of the sale, the chief executive officer directly owned 255,501 shares of the company's stock, valued at approximately $11,952,336.78. This represents a 3.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 51,828 shares of company stock valued at $2,578,097. 4.10% of the stock is currently owned by insiders. </p><h2>Hedge Funds Weigh In On CRISPR Therapeutics</h2><p>Institutional investors have recently made changes to their positions in the stock. Mcguire Capital Advisors Inc. bought a new position in shares of  CRISPR Therapeutics during the fourth quarter valued at approximately $25,000.  Ramirez Asset Management Inc. bought a new position in shares of  CRISPR Therapeutics during the fourth quarter valued at approximately $26,000.  Rothschild Investment LLC grew its holdings in shares of  CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company's stock valued at $29,000 after purchasing an additional 502 shares during the last quarter.  Thurston Springer Miller Herd &amp; Titak Inc. grew its holdings in shares of  CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd &amp; Titak Inc. now owns 576 shares of the company's stock valued at $30,000 after purchasing an additional 382 shares during the last quarter.  Finally, Optiver Holding B.V. grew its holdings in shares of  CRISPR Therapeutics by 71.4% during the third quarter. Optiver Holding B.V. now owns 504 shares of the company's stock valued at $33,000 after purchasing an additional 210 shares during the last quarter. 69.20% of the stock is owned by institutional investors. </p><h2>About CRISPR Therapeutics</h2> (Get Free Report)<p>CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.  </p><p>Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than CRISPR Therapeutics</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CRISPR Therapeutics Right Now?</h2><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p><p>While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRSP

ARKG

IDNA

<p>CRISPR Therapeutics AG (NASDAQ:CRSP) has seen a decrease in FY2028 earnings per share estimates from Brookline Capital Markets, dropping from $7.44 to $6.91. The company reported a quarterly EPS of ($1.28), missing estimates, with revenue of $1.46 million. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and a target price of $64.53. Recent insider sales have occurred, and institutional investors are adjusting their positions in the stock.</p>

Market Beat

CRISPR Therap

Ark Genomic Revolution ETF

iShares Genomics Immunology and Healthcare ETF

Invesco Nasdaq Biotechnology ETF

Wisdomtree BioRevolution Fund ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

iShares Biotechnology ETF

Piper Sandler Cos

Bank of America

Citizens Financial

Toronto Dominion Bank

Morgan Stanley

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

FY2028 EPS Estimates for CRSP Decreased by Analyst